Harvard Heart Letter

New guidelines update treatment of atrial fibrillation

New guidelines for treating atrial fibrillation (afib) recommend considering the new oral anticoagulant drugs apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto). Compared with warfarin, these drugs are just as effective for preventing a stroke (a serious risk with afib) but are less likely to cause dangerous bleeds in the brain. Other updates include less reliance on aspirin for clot prevention and a newer risk score to better predict a person’s risk of complications from afib. 
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »